   | Pages: 96; Description: Each summary contains the following: responsible institution; focal person; overall goals of the training; target audience and competencies; main topics included; format; language; length of training; certification if provided; evaluation modalities, countries where implemented, summary of evaluation results and successes and challenges. Abstract: This compendium aims to provide a wide ranging inventory of material, tools and trainings developed by Influenza Training Network partners to, among others, raise awareness on pandemic influenza preparedness measures, community case management, infection prevention and control, laboratory, risk communication, surveillance and outbreak investigation. |
|
 | Pages: 326; Description: The training course requires 35-hours (5 days) of direct contact with facilitators. The course will enable facilitators to deliver appropriate professional training programmes and strategies for the prevention and control of human seasonal influenza. Abstract: The course contains 10 modules which can be delivered in a modular format or as a discrete course. Contents are: 1) introduction to the programme; 2) human seasonal influenza programme planning; 3) surveillance systems and epidemiological studies; 4) laboratory issues; 5) human seasonal influenza policy; 6) vaccination; 7) targeting priority groups; 8) communication; 9) evaluation and research of seasonal human influenza; and 10) action planning. |
|
 | Pages: 44; Description: This workbook contains resources for advanced reading of participants to complement the 35-hour face to face session. Abstract: The content of the workbook equates to a minimum of six hours learning activity per module. The workbook consists of referenced materials, podcasts, web-links and related activities and questions. The references and other materials contained in this pre-programme workbook have not been systematically reviewed. They have been included to support the course content and primarily use WHO, and ECDC sources for reference. The workbook has been developed to ensure that all participants, whether undertaking individual modules or the complete programme, arrive fully prepared to participate and share their expertise, experience and practice for the benefit of the whole group. |
|
 | Pages: 60; Description: The "Human Seasonal Influenza Programme Planning" module is the second of the ten modules contained in the training course on "Development of programmes for prevention and control of seasonal influenza". Abstract: At the end of this module, participants should be able to: 1) review the national and global agenda underpinning the rational for an immunization programme for the prevention and control of HSI; 2) discuss the components of a plan to increase uptake of HSI vaccine within a multi-agency framework; 3) critically debate “Settings” as a tool to increase the uptake of HSI vaccine within a multi-agency framework; 4) critically explore the major programme components when implementing a vaccine programme for the prevention and control of HIS. |
|
 | Pages: 78; Description: The "Vaccination" module is the sixth of the ten modules contained in the training course on "Development of programmes for prevention and control of seasonal influenza". Abstract: At the end of this session participants should be able to: 1) critically debate with current vaccine, administration methods, contra-indications, special precautions; 2) critically review the logistics of an annual HSI vaccine programme within a national and international context including the cycle of supply; 3) critically debate factors that influence the efficacy of annual HSI vaccine; 4) critically discuss adverse events in relation to HSI in relation to safety, myths and reality; 5) critically appraise new developments in relation to HSI vaccines. |
|
 | Pages: 47; Description: This study was undertaken between April and September of 2008 to further define the details of the stockpile logistics and financing and was conducted as a collaboration between the World Health Organization, the Bill & Melinda Gates foundation, and Oliver Wyman. Abstract: The report defines options for the logistical design of the H5N1 vaccine stockpile and associated tradeoffs and develops potential strategies and mechanisms to finance the stockpile. This included an assessment of the key drivers of cost and design of mechanisms to manage the costs and mitigate uncertainties. |
|
 | Pages: 33; Description: This guideline provides a protocol for measuring pandemic influenza vaccine effectiveness in the target groups including in those 65 years old and above. Abstract: The protocol is designed for countries in the European Union and for those in the European Economic Area, where there are two protocols for case control studies to assess vaccine effectiveness. The protocol may be a model for other countries considering undertaking vaccine effectiveness assessments. |
|
 | Pages: 21; Description: This guideline provides mechanisms to estimate the relative risk (RR) of defined outcome(s) in vaccinated versus unvaccinated individuals of a defined target group for pandemic and seasonal influenza vaccine effectiveness. Abstract: This is a generic outline protocol that needs to be adapted to country-specific priorities and needs. The generic protocol includes the minimum requirements to be included in the cohort study protocols for seasonal and pandemic influenza. It represents the state of knowledge about the pandemic in August 2009. |
|
 | Description: Seasonal and pandemic influenza vaccines; covers development and production, safety and effectiveness Abstract: The learning objectives are 1) develop a basic understanding of how influenza vaccines are developed; 2) be familiar with the major types of vaccines and methods of vaccine production; 3) understand the importance of vaccine effectiveness and testing; 4) recognize the differences and challenges of seasonal vs. pandemic influenza vaccine development, manufacturing, and distribution. |
|
 | Description: The Global Advisory Committee on Vaccine Safety (GACVS) reviewed the safety of pandemic (H1N1) 2009 vaccines currently in use. To date, the safety data are reassuring and no unexpected safety concerns have been
identified. Ongoing vaccine safety monitoring (pharmacovigilance) is critical, including regular information
sharing with WHO by national regulatory and health authorities. |
|
Help 
of a subject heading to display the concerned documents. Publications are available in PDF 
, PPT 
, XLS 
or DOC 
format. Click on the corresponding icon to open the publication. Clicking on the bookshelf icon 
